[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.147.69. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
March 2, 2005

Subclinical Thyroid Disease and Cardiovascular Disease

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(9):1059-1060. doi:10.1001/jama.293.9.1059-b

To the Editor: In their Scientific Review and Clinical Applications article on subclinical thyroid disease,1 Dr Surks and colleagues stated that although several studies suggested that levothyroxine therapy will reduce total and low-density lipoprotein (LDL) cholesterol levels in patients with subclinical hypothyroidism,2 this finding had not been confirmed in randomized placebo-controlled trials, including a study for which 2 of us were authors.3 This is not accurate. In our study, patients with subclinical hypothyroidism had total and LDL cholesterol levels significantly higher than controls, which correlated with baseline serum thyrotropin (TSH) levels. Six months of levothyroxine therapy resulted in a significant decrease of both total and LDL cholesterol concentrations proportional to the baseline levels (–8.0% and –10.2%, respectively). Although greater improvement in total and LDL cholesterol levels was detected in patients with TSH levels of more than 6.0 mIU/L (–11.3% and –15.6%, respectively), reduction in both total and LDL cholesterol concentrations was also observed in patients with lower TSH levels (–6.7%, P< .05 and –8.3%, P = .08, respectively). Overall, these findings suggest that the increase in total and LDL cholesterol levels in patients with subclinical hypothyroidism is related to TSH levels, and that a minimal treatment-induced change in TSH concentration can have a measurable effect on lipoprotein profile.

First Page Preview View Large
First page PDF preview
First page PDF preview
×